RESUMEN
Pimpinella pruatjan Molk is native to Java and well known as aphrodisiac in traditional medicine. A water-boiled extract of the plant has been used in the treatment of erectile dysfunction (ED). No study has been found on the phytochemical constituents and identification of corresponding biological activities in water and polar extract. This study is aimed to identify phytoconstituents of a decoction and ethanol extract from the aerial parts of P. pruatjan Molk. Liquid chromatography-tandem mass spectroscopy (LC-MS/MS) was used to analyze and predict the bioactive compounds in both extracts. LC-MS/MS revealed both extracts contained two important compounds: Luteolin-7-O-ß-D glucopyranoside and Undulatoside A. Luteolin and Luteolin glucoside are also found in P.anisum L. Lutein 7-O glucoside was found in water extract, while more bioactive compounds, including populnin, 3,5-O-dicaffeoylquinic acid, quercetin-3'- O glucoside, methylophiopogononeone-A, kaempferol-7-O-α-L-arabinofuranoside, and 7-hydroxy-3,5,6,3',4'- pentamethoxyflavone, were found in ethanol extract. Accumulation of flavonoids, phenols, phenylpropanoids, alkaloids, and furanochromone in low quantities was observed in both extracts. This is the first report providing evidence justifying its use as a traditional medicine. Further investigation into the pharmacology mechanism of action is required.
RESUMEN
The metabolic syndrome (MS) is a multifactorial syndrome associated with a significant economic burden and healthcare costs. MS management often requires multiple treatments (polydrug) to ameliorate conditions such as diabetes mellitus, insulin resistance, obesity, cardiovascular diseases, hypertension, and non-alcoholic fatty liver disease (NAFLD). However, various therapeutics and possible drug-drug interactions may also increase the risk of MS by altering lipid and glucose metabolism and promoting weight gain. In addition, the medications cause side effects such as nausea, flatulence, bloating, insomnia, restlessness, asthenia, palpitations, cardiac arrhythmias, dizziness, and blurred vision. Therefore, is important to identify and develop new safe and effective agents based on a multi-target approach to treat and manage MS. Natural products, such as curcumin, have multi-modalities to simultaneously target several factors involved in the development of MS. This review discusses the recent preclinical and clinical findings, and up-to-date meta-analysis from Randomized Controlled Trials regarding the effects of curcumin on MS, as well as the metabonomics and a pharma-metabolomics outlook considering curcumin metabolites, the gut microbiome, and environment for a complementary personalized prevention and treatment for MS management.
RESUMEN
We previously annotated the phytochemical constituents of a root extract from Ximenia americana var. caffra and highlighted its hepatoprotective and hypoglycemic properties. We here extended our study on the leaf extract and identified its phytoconstituents using HPLC-PDA-ESI-MS/MS. In addition, we explored its antioxidant, antibacterial, and antiaging activities in vitro and in an animal model, Caenorhabditis elegans. Results from HPLC-PDA-ESI-MS/MS confirmed that the leaves contain 23 secondary metabolites consisting of condensed tannins, flavonol glycosides, flavone glycosides, and flavonol diglycosides. The leaf extract demonstrated significant antioxidant activity in vitro with IC50 value of 5 µg/mL in the DPPH assay and 18.32 µg/mL in the FRAP assay. It also inhibited four enzymes (collagenase, elastase, hyaluronidase, and tyrosinase) crucially involved in skin remodeling and aging processes with comparable activities to reference drugs along with four pure secondary metabolites identified from the extract. In accordance with the in vitro result, in vivo tests using two transgenic strains of C. elegans demonstrated its ability to reverse oxidative stress. Evidence included an increased survival rate in nematodes treated with the prooxidant juglone to 68.9% compared to the 24.8% in untreated worms and a reduced accumulation of intracellular reactive oxygen species (ROS) in a dose-dependent manner to 77.8%. The leaf extract also reduced levels of the expression of HSP 16.2 in a dose-dependent manner to 86.4%. Nuclear localization of the transcription factor DAF-16 was up to 10 times higher in worms treated with the leaf extract than in the untreated worms. The extract also inhibited the biofilm formation of Pseudomonas aeruginosa (a pathogen in skin infections) and reduced the swimming and swarming mobilities in a dose-dependent fashion. In conclusion, leaves of X. americana are a promising candidate for preventing oxidative stress-induced conditions, including skin aging.
Asunto(s)
Cosmecéuticos , Olacaceae , Animales , Antibacterianos/farmacología , Antioxidantes/metabolismo , Caenorhabditis elegans/metabolismo , Cosmecéuticos/metabolismo , Cosmecéuticos/farmacología , Glicósidos/farmacología , Olacaceae/metabolismo , Estrés Oxidativo , Fitoquímicos/farmacología , Extractos Vegetales/química , Especies Reactivas de Oxígeno/metabolismo , Espectrometría de Masas en TándemRESUMEN
Diabetes mellitus (DM) is a metabolic disorder with growing global incidence, as 387 million people were diagnosed in 2014 with an expected projection of 642 million in 2040. Several complications are associated with DM including heart attack, stroke, kidney failure, blindness, and cancer. The latter is the second leading cause of death worldwide accounting for one in every six deaths, with liver, pancreas, and endometrium cancers are the most abundant among patients with diabetes. Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway plays a vital role in developing a wide array of pathological disorders, among them diabetes and cancer. Natural secondary metabolites that counteract the deleterious effects of reactive oxygen species (ROS) and modulate PI3K/Akt/mTOR pathway could be a promising approach in cancer therapy. Here, 717 medicinal plants with antidiabetic activities were highlighted along with 357 bioactive compounds responsible for the antidiabetic activity. Also, 43 individual plant compounds with potential antidiabetic activities against cancer via the modulation of PI3K/Akt/mTOR cascade were identified. Taken together, the available data give an insight of the potential of repurposing medicinal plants and/or the individual secondary metabolites with antidiabetic activities for cancer therapy.